183 related articles for article (PubMed ID: 37834964)
1. The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate.
Matsumoto T; Wada H; Shiraki K; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834964
[TBL] [Abstract][Full Text] [Related]
2. A Clot Waveform Analysis of Thrombin Time Using a Small Amount of Thrombin Is Useful for Evaluating the Clotting Activity of Plasma Independent of the Presence of Emicizumab.
Wada H; Shiraki K; Matsumoto T; Suzuki K; Yamashita Y; Tawara I; Shimpo H; Shimaoka M
J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294464
[TBL] [Abstract][Full Text] [Related]
3. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
4. Clot Waveform Analysis for Hemostatic Abnormalities.
Wada H; Shiraki K; Matsumoto T; Shimpo H; Shimaoka M
Ann Lab Med; 2023 Nov; 43(6):531-538. PubMed ID: 37387486
[TBL] [Abstract][Full Text] [Related]
5. Clot waveform analysis for perioperative hemostatic monitoring in a hemophilia A patient on emicizumab undergoing liver transplantation.
Awane M; Wakui M; Ozaki Y; Kondo Y; Oka S; Fujimori Y; Yatabe Y; Arai T; Yamada Y; Hori S; Obara H; Hasegawa Y; Matsushita H
Clin Chim Acta; 2023 Apr; 544():117339. PubMed ID: 37076096
[TBL] [Abstract][Full Text] [Related]
6. A Clot Waveform Analysis Showing a Hypercoagulable State in Patients with Malignant Neoplasms.
Kobayashi M; Wada H; Fukui S; Mizutani H; Ichikawa Y; Shiraki K; Moritani I; Inoue H; Shimaoka M; Shimpo H
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830633
[TBL] [Abstract][Full Text] [Related]
7. The Evaluation of APTT Reagents in Reference Plasma, Recombinant FVIII Products; Kovaltry® and Jivi® Using CWA, Including sTF/7FIX Assay.
Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Sakano Y; Nishii H; Shimaoka M
Clin Appl Thromb Hemost; 2021; 27():1076029620976913. PubMed ID: 33606948
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
[TBL] [Abstract][Full Text] [Related]
9. Clot Waveform Analysis Demonstrates Low Blood Coagulation Ability in Patients with Idiopathic Thrombocytopenic Purpura.
Wada H; Ichikawa Y; Ezaki M; Shiraki K; Moritani I; Yamashita Y; Matsumoto T; Masuya M; Tawara I; Shimpo H; Shimaoka M
J Clin Med; 2021 Dec; 10(24):. PubMed ID: 34945283
[TBL] [Abstract][Full Text] [Related]
10. The Reevaluation of Thrombin Time Using a Clot Waveform Analysis.
Wada H; Ichikawa Y; Ezaki M; Matsumoto T; Yamashita Y; Shiraki K; Shimaoka M; Shimpo H
J Clin Med; 2021 Oct; 10(21):. PubMed ID: 34768360
[TBL] [Abstract][Full Text] [Related]
11. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
[TBL] [Abstract][Full Text] [Related]
12. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
13. The Detection of Hypercoagulability in Patients with Acute Cerebral Infarction Using a Clot Waveform Analysis.
Kamon T; Horie S; Inaba T; Ito N; Shiraki K; Ichikawa Y; Ezaki M; Shimpo H; Shimaoka M; Nishigaki A; Shindo A; Wada H
Clin Appl Thromb Hemost; 2023; 29():10760296231161591. PubMed ID: 36872898
[TBL] [Abstract][Full Text] [Related]
14. Detection of a Prethrombotic State in Patients with Hepatocellular Carcinoma, Using a Clot Waveform Analysis.
Fukui S; Wada H; Ikeda K; Kobayashi M; Shimada Y; Nakazawa Y; Mizutani H; Ichikawa Y; Nishiura Y; Moritani I; Yamanaka Y; Inoue H; Shimaoka M; Shimpo H; Shiraki K
Clin Appl Thromb Hemost; 2024; 30():10760296241246002. PubMed ID: 38591954
[No Abstract] [Full Text] [Related]
15. Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using different reagents: Results of a UK NEQAS proficiency testing exercise.
Lowe A; Kitchen S; Jennings I; Kitchen DP; Woods TAL; Walker ID
Haemophilia; 2020 Nov; 26(6):1087-1091. PubMed ID: 33094895
[TBL] [Abstract][Full Text] [Related]
16. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
Bowyer A; Kitchen S; Maclean R
Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
[TBL] [Abstract][Full Text] [Related]
17. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
18. In vitro validation of chromogenic substrate assay for evaluation of surrogate FVIII-activity of emicizumab.
Yamaguchi T; Shinozawa K; Nagatoishi S; Mitsuhashi A; Bingo M; Inaba H; Amano K; Tsumoto K; Kinai E
Thromb Res; 2023 Feb; 222():131-139. PubMed ID: 36657269
[TBL] [Abstract][Full Text] [Related]
19. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
20. Effects of platelet and phospholipids on clot formation activated by a small amount of tissue factor.
Wada H; Shiraki K; Matsumoto T; Ohishi K; Shimpo H; Shimaoka M
Thromb Res; 2020 Sep; 193():146-153. PubMed ID: 32559572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
